Home › Glioma › District of Columbia
Glioma clinical trials in District of Columbia
14 studies for Glioma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Johns Hopkins Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
- Children's National Hospital, Washington D.C.
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Sep 9, 2026 · NCT07664176Targeted Pediatric High-Grade Glioma Therapy
- Children's National Medical Center, Washington D.C.
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Children's National Hospital, Washington D.C.
RecruitingPhase 1/2
Ages 1 to 26 · All sexes · Updated Jul 10, 2026 · NCT06712875Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's National Medical Center, Washington D.C.
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
- Children's National Hospital, Washington D.C.
RecruitingPhase 1
Ages 4 and older · All sexes · Updated Jun 25, 2026 · NCT04573140Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Children's National Medical Center, Washington D.C.
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.